1. Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy
   Aya Saleh et al, 2021, Cancers CrossRef
2. PLAC1: biology and potential application in cancer immunotherapy
   Jafar Mahmoudian et al, 2019, Cancer Immunology, Immunotherapy CrossRef
3. Placenta-specific protein 1 (PLAC1) expression is significantly down-regulated in preeclampsia via a hypoxia-mediated mechanism
   Eric J. Devor et al, 2024, The Journal of Maternal-Fetal & Neonatal Medicine CrossRef
4. Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma
   Ryusuke Hayashi et al, 2021, OncoImmunology CrossRef
5. The potential value of cancer‐testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy
   Lina Lin et al, 2024, Immunity, Inflammation and Disease CrossRef
6. Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
   Kaipeng Xie et al, 2019, Journal of Ovarian Research CrossRef
7. Placental expression of PAPPA, PAPPA-2 and PLAC-1 in pregnacies is associated with FGR
   Stavros Sifakis et al, 2018, Molecular Medicine Reports CrossRef
8. The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells
   Eric J. Devor et al, 2021, Pharmaceuticals CrossRef
9. Characterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational Modeling
   JIANLING BI et al, 2020, Clinical Obstetrics & Gynecology CrossRef
10. Leveraging Epigenetics to Enhance the Efficacy of Cancer-Testis Antigen: A Potential Candidate for Immunotherapy
    Rashmi Gupta et al, 2022, Epigenomics CrossRef
11. Identification of placenta-specific protein 1 (PLAC-1) expression on human PC-3 cell line-derived prostate cancer stem cells compared to the tumor parental cells
    Pooya Farhangnia et al, 2024, Discover Oncology CrossRef